==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

Th1092 details
Primary information
ID1470
ThPP IDTh1092
Therapeutic Peptide/Protein NameArcitumomab
SequenceAnti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional ClassificationIIb
Molecular Weight144482.5
Chemical FormulaC6398H9900N1714O1995S54
Isoelectric Point8.26
Hydrophobicity-0.423
Melting Point (℃)61 (FAB fr
Half LifeApproximately 1 hour
DescriptionReduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/DiseaseFor imaging colorectal tumors
PharmacodynamicsBinds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of ActionBinds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesDiagnostic Agents
Patents NumberUS8420081
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetVascular endothelial growth factor A,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c
Information of corresponding available drug in the market
Brand NameCEA-Scan
CompanyN.A.
Brand DiscriptionArcitumomab, a Fab fragment of the murine monoclonal antibody IMMU-4 of the IgG1 subclass, is directed against a 200,000-dalton carcinoembryonic antigen (CEA) that is expressed on the cell surface of numerous tumors, particularly of the gastrointestinal tract (including fetal gastrointestinal tissues) and in certain inflammatory states (e.g., Crohns disease). The Fab fragment is used rather than the whole monoclonal antibody because of its more favorable pharmacokinetics (faster blood clearance and minimal liver metabolism) also, it minimizes the frequency of human anti-mouse antibody response. Less than 50% antigen complexation with technetium Tc 99m arcitumomab occurs with plasma CEA levels of up to 2000 nanograms per mL, and antigen complexation is not detectable at serum CEA levels below 250 nanograms per mL. The distribution of radioactivity is recorded by planar scintigraphy and single photon emission computed tomography (SPECT)
Prescribed forDiagnostic: Carcinoma, colorectal (diagnosis adjunct)—Technetium Tc 99m arcitumomab, in conjunction with standard diagnostic modalities (e.g., computed tomography [CT]), is indicated to detect, locate, and determine the extent of recurrent and/or metastatic colorectal carcinoma involving the liver and the extrahepatic abdominal and pelvic regions in patients with a histologically confirmed diagnosis of colorectal carcinoma. maging with technetium Tc 99m arcitumomab provides additional information in patients suspected of tumor recurrence or metastasis who have elevated or rising serum carcinoembryonic antigen (CEA) but no evidence of disease by standard diagnostic methods (e.g., abdominal and pelvic CT, chest radiograph, colonoscopy, barium enema).
Chemical NameN. A.
FormulationN. A.
Physcial AppearanceN. A.
Route of AdministrationN. A.
Recommended DosageN. A.
ContraindicationYou should not receive this medicine if you have had an allergic reaction to arcitumomab, or to products made from mice. Technetium Tc 99m arcitumomab may have a role as an adjunct to mammography in the diagnosis of primary, recurrent, or metastatic mammary cancer, particularly in patients without palpable abnormalities who have indeterminate mammograms.
Side EffectsAllergic reaction: Itching or hives, swelling in your face or hands, swelling or tingling in your mouth or throat, chest tightness, trouble breathing, Chest tightness or severe cough, Headache, Joint pain, Mild skin rash or itching, Nausea or upset stomach.
Useful Linkhttp://umm.edu/health/medical/drug-notes/notes/arcitumomab-injection http://www.drugs.com/mmx/cea-scan.html
PubMed ID20641871, 11776491, 10855627, 10656657
3-D StructureTh1092 (View) or (Download)
Primary information
ID1471
ThPP IDTh1092
Therapeutic Peptide/Protein NameArcitumomab
SequenceAnti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional ClassificationIIb
Molecular Weight144482.5
Chemical FormulaC6398H9900N1714O1995S55
Isoelectric Point8.26
Hydrophobicity-0.423
Melting Point (℃)62 (FAB fr
Half LifeApproximately 1 hour
DescriptionReduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/DiseaseFor imaging colorectal tumors
PharmacodynamicsBinds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of ActionBinds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesDiagnostic Agents
Patents NumberUS7790142
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN. A.
FormulationN. A.
Physcial AppearanceN. A.
Route of AdministrationN. A.
Recommended DosageN. A.
ContraindicationN. A.
Side EffectsN. A.
Useful LinkN. A.
PubMed ID20641871, 11776491, 10855627, 10656657
3-D StructureTh1092 (View) or (Download)
Primary information
ID1472
ThPP IDTh1092
Therapeutic Peptide/Protein NameArcitumomab
SequenceAnti-CEA heavy chain 1EVKLVESGGGLVQPGGSLRLSCATSGFT view full sequnce in fasta
Functional ClassificationIIb
Molecular Weight144482.5
Chemical FormulaC6398H9900N1714O1995S56
Isoelectric Point8.26
Hydrophobicity-0.423
Melting Point (℃)63 (FAB fr
Half LifeApproximately 1 hour
DescriptionReduced Fab fragment of the murine IgG1 monoclonal antibody IMMU-4 (also called NP-4) with specificity for carcinoembryonic antigen. Covalently labeled with Technitium 99.
Indication/DiseaseFor imaging colorectal tumors
PharmacodynamicsBinds to the carcinoembryonic antigen, which is a cell surface protein generally overexpressed in colon (and other) cancers. The radioactive Tc99, which is covalently attached to the antibody, allows radiodiagnostic detection of CEA expressing cells and tumors
Mechanism of ActionBinds selectively to cell-surface carcinoembryonic antigen (CEA) expressed on colorectal tumors.
ToxicityN.A.
MetabolismMost likely removed by opsonization via the reticuloendothelial system, or by human antimurine antibody production
AbsorptionN.A.
Volume of DistributionN.A.
ClearanceN.A.
CategoriesDiagnostic Agents
Patents NumberUS8226949
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetCarcinoembryonic antigen-related cell adhesion molecule 1
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN. A.
FormulationN. A.
Physcial AppearanceN. A.
Route of AdministrationN. A.
Recommended DosageN. A.
ContraindicationN. A.
Side EffectsN. A.
Useful LinkN. A.
PubMed ID20641871, 11776491, 10855627, 10656657
3-D StructureTh1092 (View) or (Download)